 The study found that personalized adjuvant chemotherapy based on the levels of expression of mono-resistance genes improved relapse-free and overall survival compared to standard chemotherapy in patients with non-small cell lung cancer. This suggests that personalized adjuvant chemotherapy may be beneficial for these patients. This article was authored by E.O. Rodionov, S.V. Miller, L.A.F. Teave, and others.